Vivos Therapeutics, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on September 17, 2024, by Vivos Therapeutics, Inc. (VVOS), a Delaware corporation. The report addresses Item 5.08 regarding shareholder director nominations and the scheduling of the 2024 Annual Meeting of Stockholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding corporate governance and does not contain financial statements or performance metrics.
Material Changes
The primary material change disclosed is the revision of deadlines for stockholder proposals and director nominations due to the rescheduling of the 2024 Annual Meeting. Because the meeting date is more than 30 days after the anniversary of the 2023 Annual Meeting, previously disclosed deadlines under Rule 14a-8 are no longer applicable.
Outlook, Risks, and Management Commentary
- Annual Meeting Date: The 2024 Annual Meeting is scheduled for Tuesday, November 26, 2024.
- Record Date: The record date for determining stockholders entitled to vote is set for the close of business on Friday, October 4, 2024.
- Proposal Deadlines: To be considered timely for inclusion in the proxy statement (Rule 14a-8) or for presentation at the meeting (director nominations), stockholder proposals must be received by the Company no later than September 27, 2024.
- Adjournment Policy: A public announcement of an adjournment or postponement of the meeting will not extend the time period for submitting proposals.
Key Facts for Investor Verification
- Verify the final date and location of the 2024 Annual Meeting once the definitive proxy statement is filed.
- Confirm the September 27, 2024 deadline for submitting any stockholder proposals or director nominations.
- Note that the record date for voting eligibility is October 4, 2024.
- Ensure all proposals are addressed to the Corporate Secretary at the Littleton, Colorado headquarters.